Sulfhydryl-modified nanocarriers enhance corneal retention and ocular anti-inflammatory efficacy in dry eye therapy
Acta Biomaterialia · 2025
DOI: 10.1016/j.actbio.2025.10.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Tianzuo Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; NHC Key Laboratory of Myopia and Related…. Hauptthemen laut MEDLINE: Dry Eye Syndromes, Nanoparticles, Cornea, Drug Carriers. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Changzhou Science and Technology Bureau, Program for Professor of Special Appointment Eastern Scholar at Shanghai Institutions of Higher Learning, Fudan University.
Abstract (Originalsprache)
Despite great advances in nanomedicine for targeted drug delivery, the role of nanoparticle (NP) surface chemistry in optimizing ocular therapeutics remains underexplored. Here, we employ a library of DSPE-PEG polymeric nanocarriers functionalized with distinct surface groups (-NH2, -CH3, -COOH, -Mal, -SH, -OH) to elucidate the effect of surface chemistry on ocular drug delivery. Among these, sulfhydryl-modified NPs (NP-SH) demonstrated higher cellular uptake across diverse cell types, including dendritic cells, macrophages, tumor cells and corneal epithelial cells, via interactions with membrane proteins rather than classical endocytic pathways. Based on this discovery, the immunosuppressant drug FK506 is encapsulated into NP-SH nanocarrier (FK506@NP-SH) for dry eye therapy. In vitro, FK506@NP-SH exhibits potent anti-inflammatory and anti-apoptotic effects, suppressing key mediators of ocular inflammation such as TNF-α and IL-6, as well as apoptosis. In vivo, FK506@NP-SH achieves prolonged corneal retention and significantly restores tear production, epithelial integrity, and goblet cell density in a murine dry eye model. Mechanistic studies show that NP-SH-mediated FK506 inhibition of NF-κB and MAPK signaling pathways, while comprehensive biosafety assessments confirmed minimal ocular irritation and systemic toxicity. This work provides an effective strategy for rational surface chemistry design to overcome biological barriers in drug delivery. STATEMENT OF SIGNIFICANCE: This study demonstrates that sulfhydryl-modified nanocarriers (NP-SH) enhance corneal retention and cellular uptake, improving FK506 delivery for dry eye therapy. NP-SH suppresses inflammation and apoptosis via NF-κB/MAPK pathways, restoring tear production and epithelial integrity with high biosafety. This work proposes a rational surface chemistry design to address ocular delivery challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China; NHC Key Laboratory of Myopia and Related Eye Diseases; Key Laboratory of Myopia and Related Eye Diseases, Chin…
- Department of Pharmacy, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, China.
- State Key Laboratory of Eye Health, Eye Hospital, Wenzhou Medical University, Wenzhou 325027, China.
Förderung
- Changzhou Science and Technology Bureau
- Program for Professor of Special Appointment Eastern Scholar at Shanghai Institutions of Higher Learning
- Fudan University
Zitieren
APA
Wang, T., Peng, H., Gao, Y., Chen, Z., Lu, X., Xu, R., Han, D., Wang, J., Zhou, X., Huang, J., & Luo, Z. (2025). Sulfhydryl-modified nanocarriers enhance corneal retention and ocular anti-inflammatory efficacy in dry eye therapy. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.10.014
Vancouver
Wang T, Peng H, Gao Y, Chen Z, Lu X, Xu R, et al. Sulfhydryl-modified nanocarriers enhance corneal retention and ocular anti-inflammatory efficacy in dry eye therapy. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.10.014
BibTeX
@article{Wang2025,
author = {Wang, Tianzuo and Peng, Huaidong and Gao, Yunlong and Chen, Zhongxing and Lu, Xinyi and Xu, Ruowa and Han, Danjie and Wang, Jingjie and Zhou, Xingtao and Huang, Jinhai and Luo, Zichao},
title = {Sulfhydryl-modified nanocarriers enhance corneal retention and ocular anti-inflammatory efficacy in dry eye therapy},
journal = {Acta Biomaterialia},
year = {2025},
doi = {10.1016/j.actbio.2025.10.014}
}
EUVIMED